Tag: TECVAYLI®

Clinical Data Clinical Trials Healthcare & Pharmaceuticals News Oncology

Johnson & Johnson Reports Tecvayli Multiple Myeloma Treatment Outperforms Standard Care in Phase 3 Trial

Johnson & Johnson Company Information

Johnson & Johnson has announced groundbreaking Phase 3 results for Tecvayli Multiple Myeloma Treatment, demonstrating its superiority over standard-of-care therapies in improving overall survival as early as the first relapse.

Clinical Trials Healthcare & Pharmaceuticals News Oncology

Johnson & Johnson Announces Landmark Phase 3 Results: TECVAYLI® Reduces Risk of Disease Progression or Death by 71% in Early Relapse Multiple Myeloma

JohnsonAndJohnson

Johnson & Johnson (NYSE: JNJ) today announced groundbreaking topline results from the Phase 3 MajesTEC-9 study, demonstrating that TECVAYLI® (teclistamab-cqyv) monotherapy significantly improves outcomes for [Read More…]